[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d0379fec6343909a9db410546868ae7450d8c6034dd9b4e09413f34344cfaa66",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747672440,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 134613540,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d0379fec6343909a9db410546868ae7450d8c6034dd9b4e09413f34344cfaa66"
    }
  },
  {
    "ts": null,
    "headline": "PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?",
    "summary": "Both PFE and MRK have strong product and pipeline portfolios in oncology.",
    "url": "https://finnhub.io/api/news?id=a1bc083357ba4bf251163c258d3563119fbe46644b05f47813b4768b13d70ed5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747657740,
      "headline": "PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?",
      "id": 134601634,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Both PFE and MRK have strong product and pipeline portfolios in oncology.",
      "url": "https://finnhub.io/api/news?id=a1bc083357ba4bf251163c258d3563119fbe46644b05f47813b4768b13d70ed5"
    }
  },
  {
    "ts": null,
    "headline": "I'm Putting Cash To Work: 2 Rock-Solid Dividends At Bargain Prices",
    "summary": "Discover value in overlooked sectors with Merck and Federal Realty.",
    "url": "https://finnhub.io/api/news?id=e3cfb91b36ab1670a02e7feed84ed3132ffaba51a6fdc24b75a6d2bb70f97a34",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747654562,
      "headline": "I'm Putting Cash To Work: 2 Rock-Solid Dividends At Bargain Prices",
      "id": 134585267,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover value in overlooked sectors with Merck and Federal Realty.",
      "url": "https://finnhub.io/api/news?id=e3cfb91b36ab1670a02e7feed84ed3132ffaba51a6fdc24b75a6d2bb70f97a34"
    }
  },
  {
    "ts": null,
    "headline": "IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma",
    "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., May 19, 2025--The first patient has been dosed in the IDeate-Esophageal01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus investigator’s choice of chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with disease progression following treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor.",
    "url": "https://finnhub.io/api/news?id=7e9af9139d1b8e2dc310a5f19573ab469decbaae4d62fff55cc8dc82147b32d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747652400,
      "headline": "IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma",
      "id": 134577282,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., May 19, 2025--The first patient has been dosed in the IDeate-Esophageal01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus investigator’s choice of chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with disease progression following treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor.",
      "url": "https://finnhub.io/api/news?id=7e9af9139d1b8e2dc310a5f19573ab469decbaae4d62fff55cc8dc82147b32d3"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Phase 3 trial begins in esophageal cancer",
    "summary": "Daiichi Sankyo and Merck announce the start of treatment of the first patient in a Phase III trial evaluating the efficacy of ifinatamab deruxtecan, a B7-H3-targeted antibody-drug conjugate, in...",
    "url": "https://finnhub.io/api/news?id=ad78305453bbe1467965dc50b0881328e00f7caa28b43542f632bdaf4fb3fab3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747645938,
      "headline": "Merck: Phase 3 trial begins in esophageal cancer",
      "id": 134578112,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Daiichi Sankyo and Merck announce the start of treatment of the first patient in a Phase III trial evaluating the efficacy of ifinatamab deruxtecan, a B7-H3-targeted antibody-drug conjugate, in...",
      "url": "https://finnhub.io/api/news?id=ad78305453bbe1467965dc50b0881328e00f7caa28b43542f632bdaf4fb3fab3"
    }
  },
  {
    "ts": null,
    "headline": "The Top Corporate Board Directors",
    "summary": "Who are the most influential directors at big publicly traded U.S. companies? The first annual Wall Street Journal ranking identifies 251 of them.",
    "url": "https://finnhub.io/api/news?id=066bfcda255c459bd0c85e53e67d6510547a1dc80926b2883fee079dac929bf7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747614660,
      "headline": "The Top Corporate Board Directors",
      "id": 134577269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Who are the most influential directors at big publicly traded U.S. companies? The first annual Wall Street Journal ranking identifies 251 of them.",
      "url": "https://finnhub.io/api/news?id=066bfcda255c459bd0c85e53e67d6510547a1dc80926b2883fee079dac929bf7"
    }
  }
]